October 30, 2013

Q3 2013 Marks the End of the Patent Cliff Period

 

Q3 2013 Marks the End of the Patent Cliff Period

Commenting on the Group’s performance in Q3 2013, Sanofi Chief Executive Officer, Christopher A. Viehbacher said, “The third quarter marks an inflection point for Sanofi as the impact of the patent cliff ended in August. As a result, we returned to sales growth(3) in September. Our growth platforms(4) grew 5.5% in the third quarter despite the shortage of pertussis-containing vaccines in the U.S. until mid-October, the impact of the market slowdown in China and our recovering generics business in Brazil. Growth platforms now represent 75% of our sales. We continue to make strong progress in R&D with recent approvals for Aubagio® and LemtradaTM in EU, Nasacort® Allergy 24HR for OTC use and NexGardTM in the U.S. We also released positive results for the first Phase III with alirocumab and for a large study with Fluzone® High-Dose.”